Nuevecor lands $24m Series A

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has secured $24 million in Series A financing.

21 June 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles